[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![_Investor_Feed_ Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1825090112713285632.png) Investor Feed [@_Investor_Feed_](/creator/twitter/_Investor_Feed_) on x 6270 followers
Created: 2025-07-24 06:56:37 UTC

Zydus Lifesciences Gains USFDA Tentative Approval for Key Cancer Treatment 💊 | MCap XXXXXXXX Cr

- Tentative USFDA approval for Ibrutinib tablets (140mg/280mg/420mg), a generic version of Imbruvica®
- Treats Chronic lymphocytic leukaemia (CLL), Small lymphocytic lymphoma (SLL) with 17p deletion, and Waldenstrom's macroglobulinemia (WM)
- Manufacturing at Zydus Lifesciences Ltd (SEZ), Ahmedabad
- US market sales: $2,148.9M annually (IQVIA MAT May 2025)
- Zydus group milestone: XXX approvals and XXX ANDAs filed since FY2003-04 (as of XX June 2025)

Disc: Information provided in this tweet can be inaccurate, verify through the source before making any investment decision.

![](https://pbs.twimg.com/media/Gwmqu04bsAAYD8Z.jpg)

XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1948276115723923872/c:line.svg)

**Related Topics**
[$zyduslifebo](/topic/$zyduslifebo)
[investment](/topic/investment)

[Post Link](https://x.com/_Investor_Feed_/status/1948276115723923872)